Tiziana Life Sciences Ltd is a clinical stage biotechnology company focused on developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company’s pipeline targets non active secondary progressive multiple sclerosis, multiple system atrophy, Alzheimer’s disease, and amyotrophic lateral sclerosis. Its lead asset, Foralumab TZLS 401, is a fully human anti CD3 monoclonal antibody designed to modulate T cell function and induce regulatory T cells, thereby reducing neuroinflammation. In addition to Foralumab, Tiziana is advancing TZLS 501, a fully human anti IL 6 receptor monoclonal antibody, for systemic sclerosis associated interstitial lung disease and other inflammatory indications. The firm employs a lean, virtual research and development model that leverages a network of experienced scientific advisors and external partners to concentrate resources on drug discovery and early stage clinical testing. Its mission is to deliver next generation immunotherapies that address high unmet medical needs in the central nervous system.

Tiziana Life Sciences Ltd does not yet generate revenue from product sales because none of its candidates have received regulatory approval. The company finances its operations through a combination of public equity offerings, private placements, and nondilutive grant awards from disease specific foundations. It has entered into licensing agreements with Novimmune for the Foralumab and TZLS 501 intellectual property, which involve upfront fees and royalty obligations that are recorded as expenses rather than income. Additionally, Tiziana has secured research support from institutions such as Brigham and Women’s Hospital for clinical trial execution and has pursued funding initiatives like the $3,000,000 nondilutive award sought from an Alzheimer’s foundation to advance its Phase 2a programs. These financing activities provide the capital necessary to sustain ongoing preclinical studies, clinical trials, and corporate overhead.

Within the biotechnology sector focused on neurodegenerative diseases, Tiziana Life Sciences Ltd differentiates itself by developing the only fully human anti CD3 monoclonal antibody currently in clinical testing for indications such as non active secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, multiple system atrophy and Alzheimer’s disease. Competitors include companies offering non fully human anti CD3 antibodies, small molecule immunomodulators, and alternative biologic approaches targeting pathways like amyloid beta or tau. Tiziana’s advantages stem from its proprietary nasal and oral delivery technologies that aim to reduce systemic exposure and improve tolerability, its lean R&D structure that minimizes overhead, the deep expertise of its scientific advisory board featuring leaders such as Dr. Howard Weiner and Dr. Kevan Herold, and a broad patent portfolio that protects formulations, dosing regimens, and combination therapies extending into the 2040s. These factors collectively support the company’s goal of establishing a differentiated position in a market characterized by high unmet need and limited approved therapies for progressive forms of multiple sclerosis and related disorders.

Tiziana Life Sciences Ltd engages with a variety of clinical trial sites, academic medical centers, and disease focused organizations to conduct its research and development activities. Key collaborators include Brigham and Women’s Hospital in Boston, which hosts the Expanded Access programs and early phase trials for Foralumab; Yale University, Johns Hopkins University, Cornell University, the University at Buffalo, the University of Massachusetts, and Thomas Jefferson University, which participate as investigational sites in its Phase 2a studies. The company also works with the ALS Association, which has granted funding for its amyotrophic lateral sclerosis trial, and seeks support from foundations dedicated to Alzheimer’s research. These relationships provide patient access, clinical expertise, and trial infrastructure that are essential for advancing its product candidates through the development pipeline.